Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer

subanalysis of SLCG0401 trial

Junichi Sou, Shinichi Toyooka, Norihito Okumura, Hiroshige Nakamura, Masao Nakata, Motohiro Yamashita, Junichi Sakamoto, Motoi Aoe, Katsuyuki Hotta, Satoshi Morita, Hiroshi Date

Research output: Contribution to journalArticle

Abstract

Background: Pathological stage (pStage) and histological subtype are strong determinants of the treatment strategy for non-small cell lung cancer (NSCLC). Setouchi Lung Cancer study Group (SLCG) recently reported the results of a multicenter trial (SLCG0401) indicating that paclitaxel plus carboplatin (CBDCA/PTX) as adjuvant chemotherapy does not yield better survival than uracil–tegafur (UFT) in NSCLC patients with pStage IB–IIIA disease, while stratified analyses considering the pStage and histological subtype have not been performed. Methods: We reanalyzed the overall survival (OS) and relapse-free survival (RFS) in 402 patients who had been randomly assigned to receive CBDCA/PTX or UFT by multivariate analysis with adjustments for the pStage and histological subtype. Results: There were no significant differences in the OS or RFS between the two treatment settings either in the entire cohort (n = 402) and in some of subsets: pStage IB (n = 228), pStage II (n = 117), adenocarcinoma (AD, n = 265), and squamous cell carcinoma (SQ, n = 101). In pStage IIIA patients (n = 57), CBDCA/PTX yielded superior RFS to UFT [hazard ratio (HR) 0.44; P = 0.016]. Among the patients with non-AD and non-SQ histology (n = 36), UFT yielded both superior OS and RFS to CBDCA/PTX (HRs 0.16 and 0.23; P = 0.046 and 0.011, respectively). Conclusions: There are subsets of patients in which one or the other between UFT and CBDCA/PTX is significantly more effective. Selection of adjuvant therapy for NSCLC patients needs to be made taking into consideration the pStage and histological subtype.

Original languageEnglish
JournalInternational Journal of Clinical Oncology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Carboplatin
Adjuvant Chemotherapy
Paclitaxel
Non-Small Cell Lung Carcinoma
Survival
Recurrence
Multicenter Studies
Squamous Cell Carcinoma
Lung Neoplasms
Histology
Adenocarcinoma
Therapeutics
Multivariate Analysis

Keywords

  • Adjuvant chemotherapy
  • Carboplatin
  • Non-small cell lung cancer
  • Paclitaxel
  • Uracil–tegafur

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Cite this

Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer : subanalysis of SLCG0401 trial. / Sou, Junichi; Toyooka, Shinichi; Okumura, Norihito; Nakamura, Hiroshige; Nakata, Masao; Yamashita, Motohiro; Sakamoto, Junichi; Aoe, Motoi; Hotta, Katsuyuki; Morita, Satoshi; Date, Hiroshi.

In: International Journal of Clinical Oncology, 01.01.2019.

Research output: Contribution to journalArticle

@article{b1f0c1a7d0ec48489cd8c1d264ddc503,
title = "Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial",
abstract = "Background: Pathological stage (pStage) and histological subtype are strong determinants of the treatment strategy for non-small cell lung cancer (NSCLC). Setouchi Lung Cancer study Group (SLCG) recently reported the results of a multicenter trial (SLCG0401) indicating that paclitaxel plus carboplatin (CBDCA/PTX) as adjuvant chemotherapy does not yield better survival than uracil–tegafur (UFT) in NSCLC patients with pStage IB–IIIA disease, while stratified analyses considering the pStage and histological subtype have not been performed. Methods: We reanalyzed the overall survival (OS) and relapse-free survival (RFS) in 402 patients who had been randomly assigned to receive CBDCA/PTX or UFT by multivariate analysis with adjustments for the pStage and histological subtype. Results: There were no significant differences in the OS or RFS between the two treatment settings either in the entire cohort (n = 402) and in some of subsets: pStage IB (n = 228), pStage II (n = 117), adenocarcinoma (AD, n = 265), and squamous cell carcinoma (SQ, n = 101). In pStage IIIA patients (n = 57), CBDCA/PTX yielded superior RFS to UFT [hazard ratio (HR) 0.44; P = 0.016]. Among the patients with non-AD and non-SQ histology (n = 36), UFT yielded both superior OS and RFS to CBDCA/PTX (HRs 0.16 and 0.23; P = 0.046 and 0.011, respectively). Conclusions: There are subsets of patients in which one or the other between UFT and CBDCA/PTX is significantly more effective. Selection of adjuvant therapy for NSCLC patients needs to be made taking into consideration the pStage and histological subtype.",
keywords = "Adjuvant chemotherapy, Carboplatin, Non-small cell lung cancer, Paclitaxel, Uracil–tegafur",
author = "Junichi Sou and Shinichi Toyooka and Norihito Okumura and Hiroshige Nakamura and Masao Nakata and Motohiro Yamashita and Junichi Sakamoto and Motoi Aoe and Katsuyuki Hotta and Satoshi Morita and Hiroshi Date",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10147-019-01508-9",
language = "English",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer

T2 - subanalysis of SLCG0401 trial

AU - Sou, Junichi

AU - Toyooka, Shinichi

AU - Okumura, Norihito

AU - Nakamura, Hiroshige

AU - Nakata, Masao

AU - Yamashita, Motohiro

AU - Sakamoto, Junichi

AU - Aoe, Motoi

AU - Hotta, Katsuyuki

AU - Morita, Satoshi

AU - Date, Hiroshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Pathological stage (pStage) and histological subtype are strong determinants of the treatment strategy for non-small cell lung cancer (NSCLC). Setouchi Lung Cancer study Group (SLCG) recently reported the results of a multicenter trial (SLCG0401) indicating that paclitaxel plus carboplatin (CBDCA/PTX) as adjuvant chemotherapy does not yield better survival than uracil–tegafur (UFT) in NSCLC patients with pStage IB–IIIA disease, while stratified analyses considering the pStage and histological subtype have not been performed. Methods: We reanalyzed the overall survival (OS) and relapse-free survival (RFS) in 402 patients who had been randomly assigned to receive CBDCA/PTX or UFT by multivariate analysis with adjustments for the pStage and histological subtype. Results: There were no significant differences in the OS or RFS between the two treatment settings either in the entire cohort (n = 402) and in some of subsets: pStage IB (n = 228), pStage II (n = 117), adenocarcinoma (AD, n = 265), and squamous cell carcinoma (SQ, n = 101). In pStage IIIA patients (n = 57), CBDCA/PTX yielded superior RFS to UFT [hazard ratio (HR) 0.44; P = 0.016]. Among the patients with non-AD and non-SQ histology (n = 36), UFT yielded both superior OS and RFS to CBDCA/PTX (HRs 0.16 and 0.23; P = 0.046 and 0.011, respectively). Conclusions: There are subsets of patients in which one or the other between UFT and CBDCA/PTX is significantly more effective. Selection of adjuvant therapy for NSCLC patients needs to be made taking into consideration the pStage and histological subtype.

AB - Background: Pathological stage (pStage) and histological subtype are strong determinants of the treatment strategy for non-small cell lung cancer (NSCLC). Setouchi Lung Cancer study Group (SLCG) recently reported the results of a multicenter trial (SLCG0401) indicating that paclitaxel plus carboplatin (CBDCA/PTX) as adjuvant chemotherapy does not yield better survival than uracil–tegafur (UFT) in NSCLC patients with pStage IB–IIIA disease, while stratified analyses considering the pStage and histological subtype have not been performed. Methods: We reanalyzed the overall survival (OS) and relapse-free survival (RFS) in 402 patients who had been randomly assigned to receive CBDCA/PTX or UFT by multivariate analysis with adjustments for the pStage and histological subtype. Results: There were no significant differences in the OS or RFS between the two treatment settings either in the entire cohort (n = 402) and in some of subsets: pStage IB (n = 228), pStage II (n = 117), adenocarcinoma (AD, n = 265), and squamous cell carcinoma (SQ, n = 101). In pStage IIIA patients (n = 57), CBDCA/PTX yielded superior RFS to UFT [hazard ratio (HR) 0.44; P = 0.016]. Among the patients with non-AD and non-SQ histology (n = 36), UFT yielded both superior OS and RFS to CBDCA/PTX (HRs 0.16 and 0.23; P = 0.046 and 0.011, respectively). Conclusions: There are subsets of patients in which one or the other between UFT and CBDCA/PTX is significantly more effective. Selection of adjuvant therapy for NSCLC patients needs to be made taking into consideration the pStage and histological subtype.

KW - Adjuvant chemotherapy

KW - Carboplatin

KW - Non-small cell lung cancer

KW - Paclitaxel

KW - Uracil–tegafur

UR - http://www.scopus.com/inward/record.url?scp=85068968191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068968191&partnerID=8YFLogxK

U2 - 10.1007/s10147-019-01508-9

DO - 10.1007/s10147-019-01508-9

M3 - Article

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -